Biotech Values

[Bio_pete]

ALTU - The recently announced financing and the news of Eurands successful Phase III trial for pancreatic enzyme replacement therapy should place pressure on the stock price.

"Company’s Pancreatic Enzyme Replacement Therapy Significantly Improved Absorption of Fat and Protein during Clinical Trials

Milan, Italy; Dayton, Ohio -- April 4, 2007 - Eurand, a global specialty pharmaceutical company, today unveiled data from two phase III clinical trials on its lead product candidate, ZentaseTM, formerly EUR-1008, for the treatment of Exocrine Pancreatic Insufficiency (EPI). The US Food and Drug Administration (FDA) granted fast track status for Zentase for the treatment of EPI. The company intends to file for FDA approval during the second quarter of 2007 for this potentially first-in-class pancreatic enzyme replacement therapy."



http://www.eurand.com/News--events/News2...